Roche links BTK inhibitor to low relapse rate across 96-week multiple sclerosis trial
Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis, providing evidence of durability over 96 weeks to build out its case ahead of the release of pivotal trial results.
Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis, providing evidence of durability over 96 weeks to build out its case ahead of the release of pivotal trial results.
